192 related articles for article (PubMed ID: 21041720)
1. CIITA enhances HIV-1 attachment to CD4+ T cells leading to enhanced infection and cell depletion.
Porter KA; Kelley LN; Nekorchuk MD; Jones JH; Hahn AB; de Noronha CM; Harton JA; Duus KM
J Immunol; 2010 Dec; 185(11):6480-8. PubMed ID: 21041720
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells.
Satoh A; Toyota M; Ikeda H; Morimoto Y; Akino K; Mita H; Suzuki H; Sasaki Y; Kanaseki T; Takamura Y; Soejima H; Urano T; Yanagihara K; Endo T; Hinoda Y; Fujita M; Hosokawa M; Sato N; Tokino T; Imai K
Oncogene; 2004 Nov; 23(55):8876-86. PubMed ID: 15467734
[TBL] [Abstract][Full Text] [Related]
3. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
[TBL] [Abstract][Full Text] [Related]
4. HLA-DR is involved in the HIV-1 binding site on cells expressing MHC class II antigens.
Mann DL; Read-Connole E; Arthur LO; Robey WG; Wernet P; Schneider EM; Blattner WA; Popovic M
J Immunol; 1988 Aug; 141(4):1131-6. PubMed ID: 2840463
[TBL] [Abstract][Full Text] [Related]
5. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity.
Sartoris S; Valle MT; Barbaro AL; Tosi G; Cestari T; D'Agostino A; Megiovanni AM; Manca F; Accolla RS
J Immunol; 1998 Jul; 161(2):814-20. PubMed ID: 9670958
[TBL] [Abstract][Full Text] [Related]
6. CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant.
Zhou H; Su HS; Zhang X; Douhan J; Glimcher LH
J Immunol; 1997 May; 158(10):4741-9. PubMed ID: 9144488
[TBL] [Abstract][Full Text] [Related]
7. Discoordinate surface expression of IFN-gamma-induced HLA class II proteins in nonprofessional antigen-presenting cells with absence of DM and class II colocalization.
Muczynski KA; Anderson SK; Pious D
J Immunol; 1998 Apr; 160(7):3207-16. PubMed ID: 9531276
[TBL] [Abstract][Full Text] [Related]
8. Differential presentation of HLA-DR, DQ, and DP restriction elements by interferon-gamma-treated dermal fibroblasts.
Maurer DH; Hanke JH; Mickelson E; Rich RR; Pollack MS
J Immunol; 1987 Aug; 139(3):715-23. PubMed ID: 3110281
[TBL] [Abstract][Full Text] [Related]
9. Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL).
Cycon KA; Rimsza LM; Murphy SP
Exp Hematol; 2009 Feb; 37(2):184-194. PubMed ID: 19081173
[TBL] [Abstract][Full Text] [Related]
10. Differential surface expression of class II isotypes on activated CD4 and CD8 cells correlates with levels of locus-specific mRNA.
Diedrichs M; Schendel DJ
J Immunol; 1989 May; 142(9):3275-80. PubMed ID: 2785139
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic infiltration but not diabetes occurs in the relative absence of MHC class II-restricted CD4 T cells: studies using NOD/CIITA-deficient mice.
Mora C; Wong FS; Chang CH; Flavell RA
J Immunol; 1999 Apr; 162(8):4576-88. PubMed ID: 10201997
[TBL] [Abstract][Full Text] [Related]
12. Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes.
Kaiser P; Joos B; Niederöst B; Weber R; Günthard HF; Fischer M
J Virol; 2007 Sep; 81(18):9693-706. PubMed ID: 17609262
[TBL] [Abstract][Full Text] [Related]
13. CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells.
Meissner M; Whiteside TL; Kaufmann R; Seliger B
Arch Dermatol Res; 2009 Feb; 301(2):189-93. PubMed ID: 19104823
[TBL] [Abstract][Full Text] [Related]
14. A steady state of CD4+ T cell memory maturation and activation is established during primary subtype C HIV-1 infection.
Maenetje P; Riou C; Casazza JP; Ambrozak D; Hill B; Gray G; Koup RA; de Bruyn G; Gray CM
J Immunol; 2010 May; 184(9):4926-35. PubMed ID: 20363974
[TBL] [Abstract][Full Text] [Related]
15. Modulation of specific surface receptors and activation sensitization in primary resting CD4+ T lymphocytes by the Nef protein of HIV-1.
Keppler OT; Tibroni N; Venzke S; Rauch S; Fackler OT
J Leukoc Biol; 2006 Mar; 79(3):616-27. PubMed ID: 16365153
[TBL] [Abstract][Full Text] [Related]
16. Two newly diagnosed HLA class II-deficient patients identified by rapid vector-based complementation analysis reveal discoordinate invariant chain expression levels.
Schmetterer KG; Seidel MG; Körmöczi U; Rottal A; Schwarz K; Matthes-Martin S; Steinberger P; Pickl WF
Int Arch Allergy Immunol; 2010; 152(4):390-400. PubMed ID: 20197681
[TBL] [Abstract][Full Text] [Related]
17. Nef alleles from children with non-progressive HIV-1 infection modulate MHC-II expression more efficiently than those from rapid progressors.
Schindler M; Wildum S; Casartelli N; Doria M; Kirchhoff F
AIDS; 2007 May; 21(9):1103-7. PubMed ID: 17502720
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo evidence for high frequency of I-Ab-reactive CD4+ T cells in HLA-DQ or HLA-DRA transgenic mice lacking endogenous MHC class I and/or class II expression.
Ishimoto T; Yamamoto K; Fukui Y; Fukuda Y; Dohi K; Sasazuki T
J Immunol; 1997 Oct; 159(8):3717-22. PubMed ID: 9378957
[TBL] [Abstract][Full Text] [Related]
19. Induction of CIITA and modification of in vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-gamma: similarities and distinctions with respect to HLA-DR-constitutive B cells.
Rigaud G; De Lerma Barbaro A; Nicolis M; Cestari T; Ramarli D; Riviera AP; Accolla RS
J Immunol; 1996 Jun; 156(11):4254-8. PubMed ID: 8666795
[TBL] [Abstract][Full Text] [Related]
20. Conserved residues of the bare lymphocyte syndrome transcription factor RFXAP determine coordinate MHC class II expression.
Long AB; Ferguson AM; Majumder P; Nagarajan UM; Boss JM
Mol Immunol; 2006 Feb; 43(5):395-409. PubMed ID: 16337482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
